Display options
Cite
Garala K, Joshi P, Shah M, et al. Formulation and evaluation of periodontal in situ gel. Int J Pharm Investig. 2013;3(1):29-41doi: 10.4103/2230-973X.108961.
Garala, K., Joshi, P., Shah, M., Ramkishan, A., & Patel, J. (2013). Formulation and evaluation of periodontal in situ gel. International journal of pharmaceutical investigation, 3(1), 29-41. https://doi.org/10.4103/2230-973X.108961
Garala, Kevin, et al. "Formulation and evaluation of periodontal in situ gel." International journal of pharmaceutical investigation vol. 3,1 (2013): 29-41. doi: https://doi.org/10.4103/2230-973X.108961
Garala K, Joshi P, Shah M, Ramkishan A, Patel J. Formulation and evaluation of periodontal in situ gel. Int J Pharm Investig. 2013 Jan;3(1):29-41. doi: 10.4103/2230-973X.108961. PMID: 23799203; PMCID: PMC3687234.
Copy Download .nbib Format: NLM
Share it on

Int J Pharm Investig. 2013 Jan;3(1):29-41. doi: 10.4103/2230-973X.108961.

Formulation and evaluation of periodontal in situ gel.

International journal of pharmaceutical investigation

Kevin Garala, Parth Joshi, Malay Shah, A Ramkishan, Jaydeep Patel

Affiliations

  1. Department of Pharmaceutics, Atmiya Institute of Pharmacy, Kalawad Road, Rajkot, Gujarat, India.

PMID: 23799203 PMCID: PMC3687234 DOI: 10.4103/2230-973X.108961

Abstract

BACKGROUND: The present study was aimed to develop and optimize in situ gel for the treatment of periodontal disease.

MATERIALS AND METHODS: Temperature-sensitive in situ gel containing 0.1% w/v Chlorhexidine hydrochloride was formulated by cold method using different polymers. Preliminary study was carried out to optimize different types and concentration of polymers such as Poloxamer 188, Poloxamer 407, Gellan gum, and Carbopol 934P. Central composite design was employed for optimization of the effect of independent variables such as Poloxamer 407 and Carbopol 934P on responses such as gelation temperature, spreadability, cumulative percentage release at 2 h, and time for 50% drug release (t50 %). Each formulations were evaluated for clarity, pH, gelation temperature, spreadability, drug content, in vitro drug release, t50 %, and cumulative percentage drug release at 2 h.

RESULTS: Results of evaluation parameters revealed that the drug release, gelation temperature was considerably decreased with increasing t50 % as the concentration of each polymer was increased. The desirability function was utilized to find out optimized formulation of the factorial design. Formulation F6 showed the highest overall desirability of 0.6283 and, therefore, this formulation was considered to be the optimized formulation. The % relative error was calculated, which showed that observed responses were in close agreement with the predicted values calculated from the generated regression equations.

CONCLUSION: The clarity, pH, drug content of all formulations was found to be satisfactory. Further, all the formulations showed sustained drug release for a period of 6 h, which satisfied to treat periodontal disease.

Keywords: Carbopol 934P; chlorhexidine hydrochloride; in situ gel; periodontal disease; poloxamer 407

References

  1. J Clin Pharm Ther. 2000 Feb;25(1):21-42 - PubMed
  2. Drug Dev Ind Pharm. 2010 Apr;36(4):385-92 - PubMed
  3. J Clin Periodontol. 1986 May;13(5):461-75 - PubMed
  4. J Adv Pharm Technol Res. 2012 Jan;3(1):30-40 - PubMed
  5. Drug Deliv. 2010 Sep-Oct;17(7):520-31 - PubMed
  6. Eur J Pharm Sci. 2001 Aug;14(1):53-61 - PubMed
  7. Int J Pharm. 2002 Nov 6;248(1-2):51-60 - PubMed
  8. Drug Discov Ther. 2009 Feb;3(1):6-9 - PubMed
  9. J Control Release. 2007 Sep 26;122(2):119-34 - PubMed
  10. Eur J Pharm Biopharm. 2008 Jan;68(1):34-45 - PubMed
  11. AAPS PharmSciTech. 2006 Aug 04;7(3):67 - PubMed
  12. Eur J Pharm Biopharm. 2000 Jul;50(1):83-99 - PubMed
  13. Recent Pat Drug Deliv Formul. 2008;2(1):58-67 - PubMed
  14. AAPS PharmSciTech. 2009;10(3):977-84 - PubMed
  15. J Mater Sci Mater Med. 2010 Aug;21(8):2435-42 - PubMed
  16. Indian J Pharm Sci. 2009 Jul;71(4):421-7 - PubMed
  17. J Indian Soc Periodontol. 2011 Jul;15(3):245-9 - PubMed
  18. Drug Dev Ind Pharm. 2005 Jan;31(1):25-34 - PubMed
  19. Eur J Pharm Biopharm. 2004 Sep;58(2):409-26 - PubMed
  20. J Pharm Sci. 1996 Sep;85(9):915-9 - PubMed

Publication Types